Rapid Easy Strength Training (REST) to Improve Function in Late Stage Cancer
The purpose of this study is to determine whether a gentle physical conditioning program comprised of isotonic resistive strengthening and pedometer-directed walking can improve the physical functioning and fatigue of patients with late stage lung or colon cancer.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
|Official Title:||Phase II Randomized Controlled Trial of Rapid and Easy Strength Training to Preserve Function in Late Stage Cancer|
- Ambulatory Post Acute Care Basic Mobility Short Form [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Patient reported outcome with 18 items assessed functionality in basic mobility. Response option for all items is a 4 level Likert scale
- Ambulatory Post Acute Care Short Form Daily Activities [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Patient reported outcome with 15 items assessing functionality with respect to the performance of activities of daily living.
- Linear Analoge Self Assessment of Quality of Life [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]7 item patient reported outcome assessing over-all quality of life and quality of life domains, e.g. mental, social, etc.
- FACIT-F [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]Patient reported outcome assessing overall quality of life among patients with cancer and fatigue
|Study Start Date:||June 2010|
|Study Completion Date:||November 2010|
|Primary Completion Date:||November 2010 (Final data collection date for primary outcome measure)|
Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
No Intervention: Wait list control
Participants instructed in REST after completing week 8 outcome measures
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01334983
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|